{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:39:01Z","timestamp":1790905141585,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,9,13]],"date-time":"2007-09-13T00:00:00Z","timestamp":1189641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2007,9,13]],"date-time":"2007-09-13T00:00:00Z","timestamp":1189641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1007\/s10637-007-9081-4","type":"journal-article","created":{"date-parts":[[2007,9,12]],"date-time":"2007-09-12T14:15:21Z","timestamp":1189606521000},"page":"25-34","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity"],"prefix":"10.1007","volume":"26","author":[{"given":"Praveen","family":"Rajendran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manu","family":"Jaggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand C.","family":"Burman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,9,13]]},"reference":[{"key":"9081_CR1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/med.10053","volume":"24","author":"RH Cichewicz","year":"2004","unstructured":"Cichewicz RH, Kouzi SA (2004) Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Med Res Rev 24:90\u2013114","journal-title":"Med Res Rev"},{"key":"9081_CR2","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/nm1095-1046","volume":"1","author":"E Pisha","year":"1995","unstructured":"Pisha E, Chai H, Lee IS, Chagwedera TE, Farnsworth NR, Cordell AC et al (1995) Discovery of Betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat Med 1:1046\u20131051","journal-title":"Nat Med"},{"key":"9081_CR3","first-page":"4956","volume":"57","author":"S Fulda","year":"1997","unstructured":"Fulda S, Friesen C, Los M, Scaffidi C, Mier W, Benedict M, Nunez G, Krammer PH, Peter ME, Debatin KM (1997) Betulinic acid triggers CD95 (APO-1\/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 57:4956\u20134964","journal-title":"Cancer Res"},{"key":"9081_CR4","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1016\/S0959-8049(97)00294-3","volume":"33","author":"ML Schmidt","year":"1997","unstructured":"Schmidt ML, Kuzmanoff KL, Ling-Indeck L, Pezzuto JM (1997) Betulinic acid induces apoptosis in human neuroblastoma cell lines. Eur J Cancer 33:2007\u20132010","journal-title":"Eur J Cancer"},{"key":"9081_CR5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/(SICI)1097-0215(19990730)82:3<435::AID-IJC18>3.0.CO;2-1","volume":"82","author":"S Fulda","year":"1999","unstructured":"Fulda S, Jeremias I, Steiner HH, Pietsch T, Debatin KM (1999) Betulinic acid: a new cytotoxic agent against malignant brain-tumor cells. Int J Cancer 82:435\u2013441","journal-title":"Int J Cancer"},{"key":"9081_CR6","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/hed.10231","volume":"25","author":"D Thurnher","year":"2003","unstructured":"Thurnher D, Turhani D, Pelzmann M, Wannemacher B, Knerer B, Formanek M, Wacheck V, Selzer E (2003) Betulinic acid: a new cytotoxic compound against malignant head and neck cancer cells. Head Neck 25:732\u2013740","journal-title":"Head Neck"},{"key":"9081_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejps.2006.04.006","volume":"29","author":"A Sami","year":"2006","unstructured":"Sami A, Taru M, Salme K, Jari YK (2006) Pharmacological properties of the ubiquitous natural product betulin. Eur J Pharm Sci 29:1\u201313","journal-title":"Eur J Pharm Sci"},{"key":"9081_CR8","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.bmcl.2004.02.044","volume":"14","author":"R Mukherjee","year":"2004","unstructured":"Mukherjee R, Jaggi M, Rajendran P, Siddiqui MJ, Srivastava SK, Vardhan A, Burman AC (2004a) Betulinic acid and its derivatives as anti-angiogenic agents. Bioorg Med Chem Lett 14:2181\u20132184","journal-title":"Bioorg Med Chem Lett"},{"key":"9081_CR9","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1016\/j.bmcl.2004.04.010","volume":"14","author":"R Mukherjee","year":"2004","unstructured":"Mukherjee R, Jaggi M, Rajendran P, Srivastava SK, Siddiqui MJ, Vardhan A, Burman AC (2004b) Synthesis of 3-O-acyl\/3-benzylidene\/3-hydrazone\/3-hydrazine\/17-carboxyacryloyl ester derivatives of Betulinic acid as anti-angiogenic agents. Bioorg Med Chem Lett 14:3169\u20133172","journal-title":"Bioorg Med Chem Lett"},{"key":"9081_CR10","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1016\/j.bmcl.2004.05.034","volume":"14","author":"R Mukherjee","year":"2004","unstructured":"Mukherjee R, Jaggi M, Siddiqui MJ, Srivastava SK, Rajendran P, Vardhan A, Burman AC (2004c) Synthesis and cytotoxic activity of 3-O-acyl\/3-hydrazine \/2-bromo\/20,29-dibromo Betulinic acid derivatives. Bioorg Med Chem Lett 14:4087\u20134091","journal-title":"Bioorg Med Chem Lett"},{"key":"9081_CR11","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1128\/AEM.66.9.3850-3855.2000","volume":"66","author":"P Chatterjee","year":"2000","unstructured":"Chatterjee P, Kouzi SA, Pezzuto JM, Hamann MT (2000) Biotransformation of the antimelanoma agent Betulinic acid by Bacillus megaterium ATCC 13368. Appl Environ Microbiol 66:3850\u20133855","journal-title":"Appl Environ Microbiol"},{"key":"9081_CR12","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1021\/np000343a","volume":"63","author":"SA Kouzi","year":"2000","unstructured":"Kouzi SA, Chatterjee P, Pezzuto JM, Hamann MT (2000) Microbial transformations of the antimelanoma agent Betulinic acid. J Nat Prod 63:1653\u20131657","journal-title":"J Nat Prod"},{"key":"9081_CR13","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1021\/np010424m","volume":"65","author":"T Akihisa","year":"2002","unstructured":"Akihisa T, Takamine Y, Yoshizumi K, Tokuda H, Kimura Y, Ukiya M, Nakahara T, Yokochi T, Ichiishi E, Nishino H (2002) Microbial transformations of two lupane-type triterpenes and anti-tumor-promoting effects of the transformation products. J Nat Prod 65:278\u2013282","journal-title":"J Nat Prod"},{"key":"9081_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/004982598239236","volume":"28","author":"DFV Lewis","year":"1998","unstructured":"Lewis DFV, Dickins M, Weaver RJ, Eddershaw PJ, Goldfarb PS, Tarbit MH (1998) Molecular modeling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: Rationalization of substrate specificity and sitedirected mutagenesis experiments in the CYP2C subfamily. Xenobiotica 28:235\u2013268","journal-title":"Xenobiotica"},{"issue":"3","key":"9081_CR15","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1124\/dmd.106.012815","volume":"35","author":"Z Wen","year":"2006","unstructured":"Wen Z, Martin D, Bullock P, Lee KH, Smith PC (2006) Glucuronidation of anti-HIV drug candidate bevirimat: Identification of human UDP-glucuronosyltransferases and species differences. Drug Metab Dispos 35(3):440\u2013448","journal-title":"Drug Metab Dispos"},{"key":"9081_CR16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/1099-081X(199911)20:8<379::AID-BDD198>3.0.CO;2-C","volume":"20","author":"GO Udeani","year":"1999","unstructured":"Udeani GO, Zhao G-M, Shin YG, Cooke BP, Graham J, Beecher CWW, Kinghorn AD, Pezzuto JM (1999) Pharmacokinetics and tissue distribution of Betulinic acid in CD-1 mice. Biopharm Drug Dispos 20:379\u2013383","journal-title":"Biopharm Drug Dispos"},{"key":"9081_CR17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0378-4347(99)00291-1","volume":"732","author":"YG Shin","year":"1999","unstructured":"Shin YG, Cho KH, Chung SM, Graham J, Gupta TKD, Pezzuto JM (1999) Determination of betulinic acid in mouse blood, tumor, and tissue homogenates by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Biomed Sci Appl 732:331\u2013336","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"9081_CR18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000226898","volume":"48","author":"K Yasukawa","year":"1991","unstructured":"Yasukawa K, Takido M, Matsumoto T, Takeuchi M, Nakagawa S (1991) Sterol and triterpene derivatives from plants inhibit the effects of a tumor promoter, and sitosterol and betulinic acid inhibit tumor promotion in mouse skin two-stage carcinogenesis. Oncology 48:72\u201376","journal-title":"Oncology"},{"key":"9081_CR19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0944-7113(11)80008-5","volume":"4","author":"K Yasukawa","year":"1995","unstructured":"Yasukawa K, Yu SY, Yamanouchi S, Takido M, Akihisa T, Tamura T (1995) Some lupane-type triterpenes inhibit tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin. Phytomedicine 4:309\u2013313","journal-title":"Phytomedicine"},{"key":"9081_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0304-3835(01)00718-2","volume":"175","author":"V Zuco","year":"2002","unstructured":"Zuco V, Supino R, Righetti SC, Cleris K, Marchesi E, Gambacorti-Passerini C, Formelli F (2002) Selective cytotoxicity of betulinic acid on tumor cell lines, but not normal cells. Cancer Lett 175:17\u201325","journal-title":"Cancer Lett"},{"key":"9081_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2174\/187152006776930846","volume":"6","author":"R Mukherjee","year":"2006","unstructured":"Mukherjee R, Kumar V, Srivastava SK, Agarwal SK, Burman AC (2006) Betulinic acid derivatives as anticancer agents: structure activity relationship. Anticancer Agents Med Chem 6:271\u2013279","journal-title":"Anticancer Agents Med Chem"},{"key":"9081_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55\u201363","journal-title":"J Immunol Methods"},{"key":"9081_CR23","first-page":"448","volume":"12","author":"M Kansy","year":"2001","unstructured":"Kansy M, Fischer H, Kratzat K, Senner F, Wagner B, Parrilla I (2001) High-throughput artificial membrane permeability studies in early lead discovery and development. Pharmacokinetic Optim Drug Res 12:448\u2013464","journal-title":"Pharmacokinetic Optim Drug Res"},{"key":"9081_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/108705710100600309","volume":"6","author":"K Sugano","year":"2001","unstructured":"Sugano K, Hamada H, Machida M, Ushio H (2001) High throughput prediction of oral absorption: improvement of the composition of the lipid solution used in parallel artificial membrane permeation assay. J Biomol Screen 6:189\u2013196","journal-title":"J Biomol Screen"},{"key":"9081_CR25","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1016\/0006-2952(94)00312-2","volume":"48","author":"AD Rodrigues","year":"1994","unstructured":"Rodrigues AD (1994) Use of in vitro human metabolism studies in drug development. Biochem Pharmacol 48:2147\u20132156","journal-title":"Biochem Pharmacol"},{"key":"9081_CR26","first-page":"401","volume":"265","author":"W Tassaneeyakul","year":"1993","unstructured":"Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV, Miners JO (1993) Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401\u2013407","journal-title":"J Pharmacol Exp Ther"},{"key":"9081_CR27","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/0378-4347(93)80065-C","volume":"620","author":"G Schmitz","year":"1993","unstructured":"Schmitz G, Lepper H, Estler CJ (1993) High-performance liquid chromatographic method for the routine determination of diclofenac and its hydroxy and methoxy metabolites from in vitro systems. J Chromatogr 620:158\u2013163","journal-title":"J Chromatogr"},{"key":"9081_CR28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/0003-2697(87)90006-6","volume":"162","author":"T Kronbach","year":"1987","unstructured":"Kronbach T, Mathys D, Gut J, Catin T, Meyer UA (1987) High-performance liquid chromatographic assays for bufuralol 1-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem 162:24\u201332","journal-title":"Anal Biochem"},{"key":"9081_CR29","first-page":"688","volume":"22","author":"JT Buters","year":"1994","unstructured":"Buters JT, Korzekwa KR, Kunze KL, Omata Y, Hardwick JP, Gonzalez FJ (1994) cDNA-directed expression of human cytochrome P450 CYP3A4 using baculovirus. Drug Metab Dispos 22:688\u2013692","journal-title":"Drug Metab Dispos"},{"key":"9081_CR30","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1002\/rcm.1155","volume":"17","author":"X Cheng","year":"2003","unstructured":"Cheng X, Shin YG, Levine BS, Smith AC, Tomaszewski JE, van Breemen RB (2003) Quantitative analysis of betulinic acid in mouse, rat and dog plasma using electrospray liquid chromatography\/mass spectrometry. Rapid Commun Mass Spectrom 17:2089\u20132092","journal-title":"Rapid Commun Mass Spectrom"},{"key":"9081_CR31","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1001\/jama.281.18.1728","volume":"281","author":"MA Friedman","year":"1999","unstructured":"Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ (1999) The safety of newly approved medicines: do recent market removals mean there is a problem. JAMA 281:1728\u20131734","journal-title":"JAMA"},{"key":"9081_CR32","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1001\/jama.287.17.2215","volume":"287","author":"KE Lasser","year":"2002","unstructured":"Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH (2002) Timing of new black box warnings and withdrawals for prescription medications. JAMA 287:2215\u20132220","journal-title":"JAMA"},{"key":"9081_CR33","unstructured":"World Health Organization (2006) Cancer. Retrieved on 2007-05-24"},{"key":"9081_CR34","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1245\/ASO.2003.07.019","volume":"10","author":"O Stoeltzing","year":"2003","unstructured":"Stoeltzing O, Liu W, Reinmuth N, Parikh A, Ahmad SA, Jung YD, Fan F, Ellis LM (2003) Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis. Ann Surg Oncol 10:722\u2013733","journal-title":"Ann Surg Oncol"},{"key":"9081_CR35","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1634\/theoncologist.11-9-973","volume":"11","author":"AB Benson III","year":"2006","unstructured":"Benson AB III (2006) New approaches to the adjuvant therapy of colon cancer. Oncologist 11:973\u2013980","journal-title":"Oncologist"},{"key":"9081_CR36","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S1130-6343(06)74007-7","volume":"30","author":"R Diez-Fernandez","year":"2006","unstructured":"Diez-Fernandez R, Salinas Hernandez P, Giron-Duch C (2006) A review of chemotherapy for metastatic colon cancer. Farm Hosp 30:359\u2013369","journal-title":"Farm Hosp"},{"key":"9081_CR37","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1158\/0008-5472.CAN-06-3735","volume":"67","author":"S Chintharlapalli","year":"2007","unstructured":"Chintharlapalli S, Papineni S, Ramaiah SK, Safe S (2007) Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res 67:2816\u20132823","journal-title":"Cancer Res"},{"key":"9081_CR38","first-page":"27","volume":"3","author":"M Jaggi","year":"1995","unstructured":"Jaggi M, Mukherjee R (1995) Establishment of tumorigenic cell lines from biopsies of human colon adenocarcinomas. J Basic App Biomed 3:27\u201335","journal-title":"J Basic App Biomed"},{"key":"9081_CR39","first-page":"1049","volume":"59","author":"CD Britten","year":"1999","unstructured":"Britten CD, Hilsenbeck SG, Eckhardt G, Marty J, Mangold G, MacDonald JR, Rowinsky EK, Von Hoff DD, Weitman S (1999) Enhanced antitumor activity of 6-hyroxymethylacylfulvene in combination with Irinotecan and 5-Fluorouracil in the HT29 colon tumor xenograft model. Cancer Res 59:1049\u20131053","journal-title":"Cancer Res"},{"key":"9081_CR40","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1158\/1535-7163.MCT-05-0327","volume":"5","author":"SJ Bolin","year":"2006","unstructured":"Bolin SJ, Zhao H, Hunter K, Szanto AK, Ruggeri B (2006) The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. Mol Cancer Ther 5:1744\u20131753","journal-title":"Mol Cancer Ther"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-007-9081-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-007-9081-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-007-9081-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-007-9081-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:27:18Z","timestamp":1678559238000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-007-9081-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,13]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["9081"],"URL":"https:\/\/doi.org\/10.1007\/s10637-007-9081-4","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,13]]},"assertion":[{"value":"17 July 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}